fbpx
PROGRAM
October 8-10, 2021
Asia (Beijing)
UTC +8

Plenary session 1 (5.30 pm – 6.35 pm)

Real-world data, Covid-19 & biomarkers

  • Heart failure in the real world in 2021 – Lars Lund (Sweden)
  • Biomarkers in HF for diagnosis & treatment
    guidance – Update 2021
    James Januzzi (USA)
  • Managing HF patients in COVID-19 times
    Pedro Schwartzmann (Brazil)
  • New devices to guide HF therapy
  • Big data and AI for heart failure – What is on the horizon?
    Vidur Mahajan (India)
  • Panel discussion
Europe/Middle East (Athens)
UTC +3

Plenary session 3 (5.30 pm – 6.35 pm)

State of the art management of chronic HF

  • RAASi/ARNi, MRAs and beta blockers
    Michael Böhm (Germany)
  • SGLT2 inhibitors overview 2021
    John McMurray (UK)
  • What do HF physicians needs to learn from CKD trials?
    Mark Petrie (UK)
  • SGLT2 inhibitors: focus on renal outcomes
    Milton Packer (USA)
  • Vericiguat, the new drug
    Burkert Pieske (Germany)
  • Panel discussion
Americas (New York)
UTC -4

Plenary session 5 (5.30 pm – 6.35 pm)

Update on advanced HF, assist devices and heart transplantation

  • What about patients with LVEEF <20%
  • Mechanical circulatory support (MCS)
    Tuvia Ben Gal (Israel)
  • Organising cardiac surgery and interventional care for HF
    Terrence M. Yau (Canada)
  • Destination LVAD
    Mandeep Mehra (USA)
  • Heart transplantation
    Anuradha Lala-Trindade (USA)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 2 (7.40 pm – 8.45 pm)

The new HF guidelines: diagnostic & treatment algorithms

  • Diagnostic algorithm for heart failure
    Justin Ezekowitz (USA)
  • Diagnostic approaches in HFpEF
    Justin Ezekowitz (USA)
  • HfrEF vs. HfmrEF vs. HfpEF – Similarities and differences
    Yuri Lopatin (Russia)
  • Treatment algorithm of HfrEF
    Marco Metra (Italy)
  • Treatment approaches in HfpEF
    Kavita Sharma (USA)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 4 (7.40 pm – 8.45 pm)

Acute HF and the transition to ambulatory care

  • Management of AHF – An overview
  • Post MI heart failure
    Javed Butler (USA)
  • Inflammatory cardiomyopathy and viral myocarditis
    Biykem Bozkurt (USA)
  • Cardiogenic shock
    Yuhui Zhang (China)
  • Starting new drugs classes in hospital & organizing the discharge process
    Ovidiu Chioncel (Romania)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 6 (7.40 pm – 8.45 pm)

Difficult problems in HF

  • HF patients with a suspicion of amyloid
    Shelley Zieroth (Canada)
  • Heart failure in women – What is important to know?
    Karen Sliwa-Hahnle (South Africa)
  • Individualised management: the patient with ischemic heart failure
    Giuseppe Rosano (UK)
  • Management of heart failure in low resource settings
    Clara Ines Saldarriaga (Colombia)
  • The patient with cancer and cardio-toxic chemotherapy
    Alexander Lyon (UK)
  • Panel discussion
Asia (Beijing)
UTC +8

Plenary session 7 (5.30 pm – 6.35 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 1)

  • What can the patients with poor QoL teach us?
    John Spertus (USA)
  • Sleep Apnea
    Andrew J. S. Coats (Australia)
  • Prevention of Atrial Fibrillation
    John Atherton (Australia)
  • Treatment of Atrial Fibrillation
    Paulus Kirchhof (Germany)
  • Managing obesity, frailty and cachexia
    Magdy Abdelhamid (Egypt)
  • Panel discussion
Europe/Middle East (Athens)
UTC +3

Plenary session 9 (5.30 pm – 6.35 pm)

Valvular heart disease in HF

  • State of art for imaging for diagnosis of valvular disease and assessment of risk
    Fausto Pinto (Portugal)
  • Aortic valve disease
  • Tricuspid disease
    William T. Abraham (USA)
  • Mitral valve disease – Focus on MitraClip
    Gregg Stone (USA)
  • Mitral valve disease – Focus on Carillon
    Horst Sievert (Germany)
  • Panel discussion
Americas (New York)
UTC -4

Plenary session 2 (5.30 pm – 6.35 pm)

The new HF guidelines: diagnostic & treatment algorithms

  • Diagnostic algorithm for heart failure
    Justin Ezekowitz (USA)
  • Diagnostic approaches in HFpEF
    Justin Ezekowitz (USA)
  • HfrEF vs. HfmrEF vs. HfpEF – Similarities and differences
    Yuri Lopatin (Russia)
  • Treatment algorithm of HfrEF
    Marco Metra (Italy)
  • Treatment approaches in HfpEF
    Kavita Sharma (USA)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 8 (7.40 pm – 8.45 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 2)

  • CKD
    Gianluigi Savarese (Italy)
  • Diabetes in HF
    John Cleland (UK)
  • Diabetic Kidney Disease
    Gerasimos Filippatos (Greece)
  • Hyperkalemia
    Mikhail Kosiborod (USA)
  • ID with and without anaemia
    Stefan Anker (Germany)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 1 (7.40 pm – 8.45 pm)

Real-world data, Covid-19 & biomarkers

  • Heart failure in the real world in 2021 – Lars Lund (Sweden)
  • Biomarkers in HF for diagnosis & treatment
    guidance – Update 2021
    James Januzzi (USA)
  • Managing HF patients in COVID-19 times
    Pedro Schwartzmann (Brazil)
  • New devices to guide HF therapy
  • Big data and AI for heart failure – What is on the horizon?
    Vidur Mahajan (India)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 3 (7.40 pm – 8.45 pm)

State of the art management of chronic HF

  • RAASi/ARNi, MRAs and beta blockers
    Michael Böhm (Germany)
  • SGLT2 inhibitors overview 2021
    John McMurray (UK)
  • What do HF physicians needs to learn from CKD trials?
    Mark Petrie (UK)
  • SGLT2 inhibitors: focus on renal outcomes
    Milton Packer (USA)
  • Vericiguat, the new drug
    Burkert Pieske (Germany)
  • Panel discussion
Asia (Beijing)
UTC +8

Plenary session 4 (5.30 pm – 6.35 pm)

Acute HF and the transition to ambulatory care

  • Management of AHF – An overview
  • Post MI heart failure
    Javed Butler (USA)
  • Inflammatory cardiomyopathy and viral myocarditis
    Biykem Bozkurt (USA)
  • Cardiogenic shock
    Yuhui Zhang (China)
  • Starting new drugs classes in hospital & organizing the discharge process
    Ovidiu Chioncel (Romania)
  • Panel discussion
Europe/Middle East (Athens)
UTC +3

Plenary session 6 (5.30 pm – 6.35 pm)

Difficult problems in HF

  • HF patients with a suspicion of amyloid
    Shelley Zieroth (Canada)
  • Heart failure in women – What is important to know?
    Karen Sliwa-Hahnle (South Africa)
  • Individualised management: the patient with ischemic heart failure
    Giuseppe Rosano (UK)
  • Management of heart failure in low resource settings
    Clara Ines Saldarriaga (Colombia)
  • The patient with cancer and cardio-toxic chemotherapy
    Alexander Lyon (UK)
  • Panel discussion
Americas (New York)
UTC -4

Plenary session 8 (5.30 pm – 6.35 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 2)

  • CKD
    Gianluigi Savarese (Italy)
  • Diabetes in HF
    John Cleland (UK)
  • Diabetic Kidney Disease
    Gerasimos Filippatos (Greece)
  • Hyperkalemia
    Mikhail Kosiborod (USA)
  • ID with and without anaemia
    Stefan Anker (Germany)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 5 (7.40 pm – 8.45 pm)

Update on advanced HF, assist devices and heart transplantation

  • What about patients with LVEEF <20%
  • Mechanical circulatory support (MCS)
    Tuvia Ben Gal (Israel)
  • Organising cardiac surgery and interventional care for HF
    Terrence M. Yau (Canada)
  • Destination LVAD
    Mandeep Mehra (USA)
  • Heart transplantation
    Anuradha Lala-Trindade (USA)
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Plenary session 7 (7.40 pm – 8.45 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 1)

  • What can the patients with poor QoL teach us?
    John Spertus (USA)
  • Sleep Apnea
    Andrew J. S. Coats (Australia)
  • Prevention of Atrial Fibrillation
    John Atherton (Australia)
  • Treatment of Atrial Fibrillation
    Paulus Kirchhof (Germany)
  • Managing obesity, frailty and cachexia
    Magdy Abdelhamid (Egypt)
  • Panel discussion
Break (6.35 pm – 6.45 pm)

Plenary session 10 (6.45 pm – 7.30 pm)

The need for Global Cascade Guidelines: Key Points in the HF Guideline Approach

  • HF Guidelines in China
    Jian Zhang (China)
  • HF Guidelines in India
    Vijay Chopra (India)
  • HF Guidelines in Japan
    Hiroyuki Tsutsui (Japan)
  • HF Guidelines in Russia
    Evgeny Shlyakhto (Russia)
  • HF Guidelines in Canada
    Shelley Zieroth (Canada)
  • HF Guidelines for Australia / New Zealand
    John Atherton (Australia)
  • HF Guidelines for South-East Asia
    David Sim (Singapore)
  • HF Guidelines for South America
    Jose Luis Navarro Estrada (Argentina)
  • Panel discussion
Break (7.30 pm – 7.40 pm)

Plenary session 9 (7.40 pm – 8.45 pm)

Valvular heart disease in HF

  • State of art for imaging for diagnosis of valvular disease and assessment of risk
    Fausto Pinto (Portugal)
  • Aortic valve disease
  • Tricuspid disease
    William T. Abraham (USA)
  • Mitral valve disease – Focus on MitraClip
    Gregg Stone (USA)
  • Mitral valve disease – Focus on Carillon
    Horst Sievert (Germany)
  • Panel discussion